GLP-1s Are Not Just a Weight Loss Story
GLP-1 medications are being studied for effects that may extend beyond weight loss, including cardiometabolic outcomes and behavior-related pathways.
18 min readRead->
Medicine
Semaglutide
Evidence-aware explainers on semaglutide products, labels, obesity medicine, cardiometabolic outcomes, and safety.
1 published articleBuilding this topic
Related research
STEP 1: Once-weekly semaglutide in adults with overweight or obesitySTEP 4: Effect of continued weekly semaglutide vs placebo on weight loss maintenanceSTEP 5: Two-year effects of semaglutide in adults with overweight or obesitySELECT: Semaglutide and cardiovascular outcomes in obesity without diabetesFLOW: Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes
Useful source library entries
FDA approves Wegovy to reduce risk of serious heart problems in adults with obesity or overweight and cardiovascular diseaseFDA approves Wegovy for metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosisFDA clarifies policies for compounders as GLP-1 supply stabilizesWegovy prescribing informationOnce-weekly semaglutide in adults with overweight or obesity
Related topics
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No miracle claims. Just better health signal.
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No miracle claims. Just better health signal.